Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

X
Trial Profile

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Ceralasertib (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Oleclumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Vistusertib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms HUDSON
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 01 Mar 2024 Results evaluating combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy, published in the Nature Medicine
    • 10 Aug 2023 Planned End Date changed from 27 Feb 2025 to 26 Sep 2024.
    • 10 Aug 2023 Planned primary completion date changed from 27 Feb 2025 to 26 Sep 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top